503A Price Audit Verified: Semaglutide $49/mo · Tirzepatide $99/mo ($0 Platform Membership · All Doses Locked) Claim $49 Rate →
Losing Weight RX Open-Data Desk
Official Wire Archive · 35 Releases 4 CERN/Zenodo DOIs · 467 Clinical Cost Records

Losing Weight RX Pressroom, Wire Releases & Open-Data Media Kit

Official announcements, consumer fee watchdog investigations, and peer-verifiable pharmacoeconomic dataset releases from the Losing Weight RX Pharmacoeconomics & Consumer Audit Desk (Dallas, TX). Media & research inquiries: [email protected].

Permanent Open-Science Repository Citations (CC BY 4.0)

Official Wire Announcements (35 Releases)

Clinical & Regulatory References

The clinical efficacy, dosing, safety, and regulatory information in Losing Weight RX Pressroom, Wire Releases & Open-Data Media Kit is supported by the following peer-reviewed studies and authoritative .gov / .edu sources:

  1. Harvard Health Publishing, Harvard Medical School. (2024). How does Ozempic work? Understanding GLP-1s for diabetes, weight loss, and beyond. https://www.health.harvard.edu/staying-healthy/how-does-ozempic-work-understanding-glp-1s-for-diabetes-weight-loss-and-beyond
  2. Ladebo, L., Ernst, M. T., Mailhac, A., Dirksen, C., Bojsen-Møller, K. N., & Pottegård, A. (2024). Real-World Use of Semaglutide for Weight Management: Patient Characteristics and Dose Titration-A Danish Cohort Study. Diabetes care, 47(10), 1834-1837. https://doi.org/10.2337/dc24-1082
  3. National Institute of Diabetes and Digestive and Kidney Diseases. (2023). Prescription medications to treat overweight and obesity. https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
  4. Overgaard, R. V., Navarria, A., Ingwersen, S. H., Bækdal, T. A., & Kildemoes, R. J. (2021). Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials. Clinical pharmacokinetics, 60(10), 1335-1348. https://doi.org/10.1007/s40262-021-01025-x
  5. Samuels, J. M., Ye, F., Irlmeier, R., Silver, H., Srivastava, G., & Spann, M. (2025). Real-world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic. Diabetes, obesity & metabolism, 27(11), 6200-6209. https://doi.org/10.1111/dom.70004
  6. U.S. Food and Drug Administration. (2025). FDA's concerns with unapproved GLP-1 drugs used for weight loss. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss